From pathogenesis to novel therapies in the treatment of primary biliary cholangitis

Vincenzo Ronca, Marco Carbone, Francesca Bernuzzi, Federica Malinverno, Hani S. Mousa, M. Eric Gershwin, Pietro Invernizzi

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Introduction: Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis and fibrosis, and leading to liver failure. Ursodeoxycholic acid (UDCA) is the first-line therapy for the treatment of PBC patients. This is effective in majority of patients; however, up to 20 percent of patients have an incomplete response to UDCA therapy and have a reduced prognosis as compared to healthy individuals. Obeticholic acid (OCA) has been recently registered as second-line therapy for patients with incomplete response to UDCA, with plans to demonstrate the long-term clinical efficacy. Areas covered: Recent evolution in our understanding of disease mechanisms is leading to the advent of new and re-purposed therapeutic agents targeting key processes in the etiopathogenesis. Several therapeutic targets have been proposed which can be categorized into three compartments: immune, biliary and fibrosis. In this review we describe the main biological mechanisms underpinning disease development and progression in PBC and the new targeted therapies on the horizon. Expert commentary: Testing new drugs towards hard clinical endpoints is challenging in PBC due to its low prevalence and the slow progression of the disease. Novel promising biomarkers are under study and should be evaluated as surrogate endpoints in clinical trials.

Original languageEnglish (US)
Pages (from-to)1121-1131
Number of pages11
JournalExpert Review of Clinical Immunology
Volume13
Issue number12
DOIs
StatePublished - Dec 2 2017

Fingerprint

Cholangitis
Ursodeoxycholic Acid
Therapeutics
Disease Progression
Fibrosis
Biomarkers
Intrahepatic Bile Ducts
Cholestasis
Liver Failure
Liver Diseases
Clinical Trials
Inflammation
Pharmaceutical Preparations

Keywords

  • ASBT antagonists
  • autoimmune liver disease
  • FGF-19
  • fibrates
  • novel therapies
  • OCA
  • Primary biliary cholangitis
  • TGR-5 agonist
  • ursodeoxycholic acid
  • Ustekinumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. / Ronca, Vincenzo; Carbone, Marco; Bernuzzi, Francesca; Malinverno, Federica; Mousa, Hani S.; Gershwin, M. Eric; Invernizzi, Pietro.

In: Expert Review of Clinical Immunology, Vol. 13, No. 12, 02.12.2017, p. 1121-1131.

Research output: Contribution to journalReview article

Ronca, V, Carbone, M, Bernuzzi, F, Malinverno, F, Mousa, HS, Gershwin, ME & Invernizzi, P 2017, 'From pathogenesis to novel therapies in the treatment of primary biliary cholangitis', Expert Review of Clinical Immunology, vol. 13, no. 12, pp. 1121-1131. https://doi.org/10.1080/1744666X.2017.1391093
Ronca, Vincenzo ; Carbone, Marco ; Bernuzzi, Francesca ; Malinverno, Federica ; Mousa, Hani S. ; Gershwin, M. Eric ; Invernizzi, Pietro. / From pathogenesis to novel therapies in the treatment of primary biliary cholangitis. In: Expert Review of Clinical Immunology. 2017 ; Vol. 13, No. 12. pp. 1121-1131.
@article{c622e2a715a14671b2c22e9b90815c05,
title = "From pathogenesis to novel therapies in the treatment of primary biliary cholangitis",
abstract = "Introduction: Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis and fibrosis, and leading to liver failure. Ursodeoxycholic acid (UDCA) is the first-line therapy for the treatment of PBC patients. This is effective in majority of patients; however, up to 20 percent of patients have an incomplete response to UDCA therapy and have a reduced prognosis as compared to healthy individuals. Obeticholic acid (OCA) has been recently registered as second-line therapy for patients with incomplete response to UDCA, with plans to demonstrate the long-term clinical efficacy. Areas covered: Recent evolution in our understanding of disease mechanisms is leading to the advent of new and re-purposed therapeutic agents targeting key processes in the etiopathogenesis. Several therapeutic targets have been proposed which can be categorized into three compartments: immune, biliary and fibrosis. In this review we describe the main biological mechanisms underpinning disease development and progression in PBC and the new targeted therapies on the horizon. Expert commentary: Testing new drugs towards hard clinical endpoints is challenging in PBC due to its low prevalence and the slow progression of the disease. Novel promising biomarkers are under study and should be evaluated as surrogate endpoints in clinical trials.",
keywords = "ASBT antagonists, autoimmune liver disease, FGF-19, fibrates, novel therapies, OCA, Primary biliary cholangitis, TGR-5 agonist, ursodeoxycholic acid, Ustekinumab",
author = "Vincenzo Ronca and Marco Carbone and Francesca Bernuzzi and Federica Malinverno and Mousa, {Hani S.} and Gershwin, {M. Eric} and Pietro Invernizzi",
year = "2017",
month = "12",
day = "2",
doi = "10.1080/1744666X.2017.1391093",
language = "English (US)",
volume = "13",
pages = "1121--1131",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - From pathogenesis to novel therapies in the treatment of primary biliary cholangitis

AU - Ronca, Vincenzo

AU - Carbone, Marco

AU - Bernuzzi, Francesca

AU - Malinverno, Federica

AU - Mousa, Hani S.

AU - Gershwin, M. Eric

AU - Invernizzi, Pietro

PY - 2017/12/2

Y1 - 2017/12/2

N2 - Introduction: Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis and fibrosis, and leading to liver failure. Ursodeoxycholic acid (UDCA) is the first-line therapy for the treatment of PBC patients. This is effective in majority of patients; however, up to 20 percent of patients have an incomplete response to UDCA therapy and have a reduced prognosis as compared to healthy individuals. Obeticholic acid (OCA) has been recently registered as second-line therapy for patients with incomplete response to UDCA, with plans to demonstrate the long-term clinical efficacy. Areas covered: Recent evolution in our understanding of disease mechanisms is leading to the advent of new and re-purposed therapeutic agents targeting key processes in the etiopathogenesis. Several therapeutic targets have been proposed which can be categorized into three compartments: immune, biliary and fibrosis. In this review we describe the main biological mechanisms underpinning disease development and progression in PBC and the new targeted therapies on the horizon. Expert commentary: Testing new drugs towards hard clinical endpoints is challenging in PBC due to its low prevalence and the slow progression of the disease. Novel promising biomarkers are under study and should be evaluated as surrogate endpoints in clinical trials.

AB - Introduction: Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by chronic inflammation of the intrahepatic bile ducts, causing progressive ductopenia, cholestasis and fibrosis, and leading to liver failure. Ursodeoxycholic acid (UDCA) is the first-line therapy for the treatment of PBC patients. This is effective in majority of patients; however, up to 20 percent of patients have an incomplete response to UDCA therapy and have a reduced prognosis as compared to healthy individuals. Obeticholic acid (OCA) has been recently registered as second-line therapy for patients with incomplete response to UDCA, with plans to demonstrate the long-term clinical efficacy. Areas covered: Recent evolution in our understanding of disease mechanisms is leading to the advent of new and re-purposed therapeutic agents targeting key processes in the etiopathogenesis. Several therapeutic targets have been proposed which can be categorized into three compartments: immune, biliary and fibrosis. In this review we describe the main biological mechanisms underpinning disease development and progression in PBC and the new targeted therapies on the horizon. Expert commentary: Testing new drugs towards hard clinical endpoints is challenging in PBC due to its low prevalence and the slow progression of the disease. Novel promising biomarkers are under study and should be evaluated as surrogate endpoints in clinical trials.

KW - ASBT antagonists

KW - autoimmune liver disease

KW - FGF-19

KW - fibrates

KW - novel therapies

KW - OCA

KW - Primary biliary cholangitis

KW - TGR-5 agonist

KW - ursodeoxycholic acid

KW - Ustekinumab

UR - http://www.scopus.com/inward/record.url?scp=85034433247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034433247&partnerID=8YFLogxK

U2 - 10.1080/1744666X.2017.1391093

DO - 10.1080/1744666X.2017.1391093

M3 - Review article

C2 - 28994348

AN - SCOPUS:85034433247

VL - 13

SP - 1121

EP - 1131

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 12

ER -